Updates are available Correction dated 2017-11-25

Article History

First Online: 20 April 2017

Change Date: 25 November 2017

Change Type: Correction

Change Details: The article Pharmacologic Complement Inhibition in Clinical Transplantation, written by Vasishta S. Tatapudi and Robert A. Montgomery, was originally published Online First without open access.

Compliance with Ethical Standards

:

: Robert Montgomery received research grants from Alexion (manufacturer of Soliris–Eculizumab) and Shire ViroPharma; served as a paid consultant for Alexion, Shire ViroPharma and CSL, Behring; and received travel honoraria from Alexion and Shire VioPharma during the conduct of this study. He served on advisory boards for Genentech Scientific/ROCHE, True North/iPerian, Novartis, and Hansa Medical; received consulting feels from OrbidMed, GuidePoint Global, Sucampo, Astellas, and Shire; and received research grants from Immune Tolerance Network, ViroPharma, Hansa and Alexion. Vasishta Tatapudi declares no conflict of interest.

: This article does not contain any studies with human or animal subjects performed by any of the authors.